RAD17 Checkpoint Clamp Loader: A Potential Drug Target (G5884)

Target Name: RAD17

NCBI ID: G5884

RAD17

RAD17 Checkpoint Clamp Loader: A Potential Drug Target

RAD17 (RAD17 checkpoint clamp loader component) is a protein that is expressed in various tissues and cells in the human body. It plays a critical role in the regulation of cell division and has been implicated in various diseases, including cancer. The checkpoint clamp loader component of RAD17 has been identified as a potential drug target or biomarker, which could be targeted by small molecules to inhibit its function and treat various diseases.

The checkpoint clamp loader component of RAD17 is a protein that is composed of 17 subunits that are held together by non-covalent interactions. It is expressed in various tissues, including the brain, heart, and gastrointestinal tract, and has been implicated in various biological processes, including cell division, apoptosis, and inflammation.

The checkpoint clamp loader component of RAD17 is involved in the regulation of cell division by preventing the separation of the sister chromatids that are generated during DNA replication. It does this by interacting with the microtubules of the

Protein Name: RAD17 Checkpoint Clamp Loader Component

Functions: Essential for sustained cell growth, maintenance of chromosomal stability, and ATR-dependent checkpoint activation upon DNA damage. Has a weak ATPase activity required for binding to chromatin. Participates in the recruitment of the RAD1-RAD9-HUS1 complex and RHNO1 onto chromatin, and in CHEK1 activation. May also serve as a sensor of DNA replication progression, and may be involved in homologous recombination

The "RAD17 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RAD17 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets